Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.7K
1.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

353
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
353
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

492
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
492
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA methylation signatures distinguish extranodal NK/T-cell lymphoma and EBV-positive nodal T/NK-cell lymphoma and identify prognostic subgroups.

Leukemia·2026
Same author

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

American journal of hematology·2026
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

Clinicopathologic features of systemic ALK-negative anaplastic large cell lymphoma with TP53 deletion.

American journal of clinical pathology·2026
Same author

Practical approaches to the diagnosis and differential diagnosis of T-lymphoblastic leukemia/lymphoma.

Human pathology·2026
Same author

Genetic Profile, Treatment Response, and Outcomes of BCR::ABL1-Positive Mixed-Phenotype Acute Leukemia: A Study From the BCR::ABL1 Pathology Group.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Related Experiment Video

Updated: Mar 17, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.3K

The evolving potential of companion diagnostics.

Joseph D Khoury1

  • 1a Division of Pathology and Laboratory Medicine, Department of Hematopathology , the University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.

Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum
|July 20, 2016
PubMed
Summary

Companion diagnostics are evolving rapidly with new targeted therapies and testing methods. Enhanced collaboration among stakeholders is crucial for advancing personalized cancer medicine and improving patient outcomes.

Keywords:
Cancercompanion diagnosticsmolecular diagnosticsnext-generation sequencing

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K

Related Experiment Videos

Last Updated: Mar 17, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Personalized Medicine

Background:

  • Companion diagnostics play a critical role in guiding targeted therapy selection for cancer patients.
  • Recent advancements in assay platforms and therapeutic approaches are reshaping the landscape of cancer diagnostics.
  • The integration of personalized medicine principles necessitates a dynamic approach to diagnostic strategies.

Purpose of the Study:

  • To analyze the significant shifts in the scope and application of companion diagnostics in oncology.
  • To highlight the impact of novel testing platforms and targeted therapies on personalized cancer care.
  • To emphasize the need for enhanced collaborations among stakeholders in companion diagnostics.

Main Methods:

  • Review of recent developments in companion diagnostics, including assay technologies and regulatory changes.
  • Analysis of the evolving relationship between diagnostic platforms and therapeutic strategies.
  • Examination of stakeholder roles and collaborations in the companion diagnostics ecosystem.

Main Results:

  • Significant evolution in companion diagnostics driven by targeted therapies and advanced testing platforms.
  • Emergence of new opportunities for personalized medicine in cancer treatment.
  • Identification of key areas of change: assay platforms, analytes, regulations, and therapeutic approaches.

Conclusions:

  • Close collaboration between stakeholders is essential for optimizing companion diagnostic performance.
  • Continued innovation in companion diagnostics is key to advancing personalized cancer medicine.
  • Ensuring optimal patient outcomes requires a coordinated approach to diagnostic and therapeutic development.